Report shows how the FDA incorporates the two ISO standards in its medical device development policy, how the EU version of the two standards differs in significant ways and how the EU Medical Device Regulation may require further changes in the European standards.

LODH RAISES NOVARTIS TARGET TO CHF100

Lombard Odier Darier Hentsch raised its target for Novartis (NVS) to CHF100 from CHF85. Says the new target is still a base case, not incorporating any early-stage pipeline drugs. "Currently, valuation does not reflect accelerating growth prospects for the Novartis flagship pharmaceuticals division," LODH says. "Newratings